期刊文献+

靶向murA反义工程菌的构建 被引量:1

Construction of murA-specific antisense engineering strains
在线阅读 下载PDF
导出
摘要 目的应用反义RNA沉默技术,构建针对murA基因的超敏工程菌。方法将不同murA基因片段插入带有paired termini结构的反义表达载体pHN678中,获得重组质粒,导入大肠埃希菌宿主诱导表达。通过生长表型考察不同反义片段对murA沉默效果的影响,并用靶向MurA抑制剂磷霉素验证反义工程菌E.coli DH5α/pHNM2的敏感性及靶向性。结果反义片段murA1和murA2具有较好的沉默效果,E.coli DH5α/pHNM2对MurA抑制剂磷霉素具有靶标特异性和敏感性。结论成功获得靶向murA反义工程菌E.coli DH5α/pHNM2,并有望进一步应用于MurA特异性抑制剂高通量筛选模型的构建。 Objective To construct murA-specific antisense engineering strains by using antisense RNA technology. Methods Three murA asRNA fragments were inserted into the paired-termini antisense RNA expression vector pHN678 respectively. The constructed plasmids were then transferred into E.coli DH5a and different transformants were obtained. Gene silencing efficacy was investigated by observing growth phenotype. MurA-specific inhibitory fosfomycin was used to validate the sensitivity and target specificity of antisense engineering strain E.coli DH5a/pHNM2. Results Fragments mural and murA2 showed the better silencing effect. E.coli DH5α/pHNM2 displayed prominent specificity and sensitivity to fosfomycin. Conclusion A sensitive engineering strain E.coli DH5α/pHNM2 was obtained and may be applied to MurA-specific screening model establishment.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2014年第6期413-417,共5页 Chinese Journal of Antibiotics
基金 国家重大新药创制专项(2012ZX09301002-003)
关键词 反义RNA技术 murA 靶向筛选 Antisense RNA technology murA Target-specific screening
  • 相关文献

参考文献20

  • 1Kahrstrom C T.Entering a post-antibiotic era[J]? Nat Rev Microbiol,2013,11(3):146-146.
  • 2Scheffler R J,Colmer S,Tynan H,et al.Antimicrobials,drug discovery,and genome mining[J].Appl Microbiol Biotechnol,2013,97(3):969-978.
  • 3马晓莉.反义RNA及其应用研究进展[J].安徽教育学院学报,1999(2X):75-78. 被引量:1
  • 4Good L,Stach J E M.Synthetic RNA silencing in bacteria-antimicrobial discovery and resistance breaking[J].Front Microbiol,2011:2.
  • 5杨剑.反义RNA技术与肿瘤研究进展[J].国外医学(肿瘤学分册),2002,29(2):83-86. 被引量:6
  • 6殷瑜,戈梅,陈代杰.新方法新技术与新型抗生素发现[J].微生物学通报,2013,40(10):1874-1884. 被引量:9
  • 7Wang J,Soisson S M,Young K,et al.Platensimycin is a selective FabF inhibitor with potent antibiotic properties[J].Nature,2006,441(7091):358-361.
  • 8Koch A L.Bacterial wall as target for attack past,present,and future research[J].Clin Microbiol Rev,2003,16(4):673-687.
  • 9Skarzynski T,Mistry A,Wonacott A,et al.Structure of UDP-N-acetylglucosamine enolpyruvyl transferase,an enzyme essential for the synthesis of bacterial peptidoglycan,complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin[J].Structure,1996,4(12):1465-1474.
  • 10Gautam A,Rishi P,Tewari R.UDP-N-acetylglucosamine enolpyruvyl transferase as a potential target for antibacterial chemotherapy:recent developments[J].Appl Microbiol Biotechnol,2011,92(2):211-225.

二级参考文献114

共引文献15

同被引文献14

  • 1殷瑜,杨志钧,陈代杰,等.基于反义RNA技术的ACP抑制剂筛选模型的构建[C].第四届全国微生物资源学术暨国家微生物资源平台运行服务研讨会论文集,中国微生物学会微生物资源专业委员会,2012.
  • 2Adams D E, Shekhtman E M, Zechiedrich E L, et al. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication[J]. Cell, 1992, 71(2): 277-288.
  • 3Belland R J, Morrison S G, lson C, et al. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates[J]. Mol Microbiol, 1994, 14(2): 371-380.
  • 4Hardy C D, Cozzarelli N R. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance[J]. Antimicrob Agents Chemother, 2003, 47(3): 941-947.
  • 5Fujimoto-Nakamura M, Ito H, Oyamada Y, et al. Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2005, 49(9): 3810-3815.
  • 6Good L, Stach J E M. Synthetic RNA silencing in bacteria- antimicrobial discovery and resistance breaking[J]. Front Microbiol, 2011, 2: 185.
  • 7Nakashima N, Tamura T, Good L. Paired termini stabilize antisense RNAs and enhance conditional gene silencing in Escherichia coli[J]. Nucl Acids Res, 2006, 34(20): e138-e138.
  • 8Wilkinson B, Bachmann B O preparation and alteration[J] 10(2): 169-176. Biocatalysis in pharmaceutical Curr Opin Chem Biol, 2006,.
  • 9Bayly A M, Berglez J M, Patel O, et al. Folic acid utilisation related to sulfa drug resistance in Saccharomyces cerevisiae[J]. FEMS Microbiol Lett, 2001,204(2): 387-390.
  • 10Orhan G, Bayram A, Zer Y, et al. Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis[ J]. J Clin Microbiol, 2005, 43( 1 ): 140-143.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部